Brivanib alaninate

Drug Profile

Brivanib alaninate

Alternative Names: BMS-540215; BMS-582664; Brivanib; ZL-2301

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Bristol-Myers Squibb; Gynecologic Oncology Group; National Cancer Institute (USA); ZAI Lab
  • Class Antineoplastics; Esters; Indoles; Pyrroles; Small molecules; Triazines
  • Mechanism of Action Angiogenesis inhibitors; Type 1 fibroblast growth factor receptor antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hepatocellular carcinoma
  • No development reported Solid tumours
  • Discontinued Cervical cancer; Colorectal cancer; Gastrointestinal cancer

Most Recent Events

  • 17 Jan 2017 Discontinued - Phase-II for Cervical cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO)
  • 15 Dec 2016 Biomarkers information updated
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease) in Canada (PO, Tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top